Senesco Technologies has completed the third cohort of its Phase Ib/IIa trial for SNS01-T in the treatment of multiple myeloma and lymphoma. The company has also received approval from its Data Review Committee to proceed to the fourth cohort, which is expected to require six evaluable patients. The Data Review Committee’s review of the results of cohort 3 concluded that SNS01-T was safe and well tolerated at a dose of 0.2 mg/Kg. No drug-related serious adverse events or dose limiting toxicities...